文献速递支持与姑息治疗

肠道微生物组与免疫检查点抑制剂毒性

Gut microbiome and immune checkpoint inhibitor toxicity.
PubMed 文献 · Eur J Cancer · 2025-01-04

这项前瞻性队列研究对195例接受抗PD-1±抗CTLA-4治疗的癌症患者进行粪便16S rRNA基因测序和宏基因组鸟枪法测序,评估基线及治疗期间肠道微生物组与严重免疫相关不良事件(irAE)的关联。结果显示,发生严重irAE的患者基线致病菌群平均相对丰度显著更高(8.2% vs 4.8%;OR 1.40;95%CI 1.07-1.87),且开始ICI后瘤胃球菌科相对丰度下降更显著。作者认为,以致病菌群相对丰度升高和瘤胃球菌科相对丰度降低为信号的肠道菌群失调可能易导致严重irAE。

要点

  • 发生严重irAE者基线致病菌群平均相对丰度8.2%,未发生者为4.8%(OR 1.40;95%CI 1.07-1.87)。
  • 开始ICI后瘤胃球菌科相对丰度下降在发生严重irAE者中较未发生者更显著。
  • 严重irAE发生时瘤胃球菌科、瘤胃球菌属及R. bromii和R. callidus相对丰度显著低于其他时间点。

核心结论

  • 以致病菌群相对丰度升高和瘤胃球菌科相对丰度降低为信号的肠道菌群失调可能易导致严重irAE。

研究设计与样本

  • 前瞻性队列研究,纳入195例接受抗PD-1±抗CTLA-4治疗的癌症患者,分析497份粪便样本(基线、开始ICI后不久、严重irAE发生时及开始免疫抑制后),采用16S rRNA基因测序和宏基因组鸟枪法测序。

主要发现

  • 基线时发生严重irAE者致病菌群平均相对丰度为8.2%,未发生者为4.8%(OR 1.40;95%CI 1.07-1.87),在ICI治疗早期及严重irAE发生时亦观察到该差异。
  • 开始ICI后瘤胃球菌科相对丰度下降在发生严重irAE者中较未发生者更显著。
  • 严重irAE发生时瘤胃球菌科、瘤胃球菌属及R. bromii和R. callidus的相对丰度显著低于其他时间点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple studies have suggested that gut microbiome may influence immune checkpoint inhibitor (ICI) efficacy, but its association with immune-related adverse events (irAEs) is less well studied. In this prospective cohort study, we assessed whether gut microbiome composition at start, or changes during ICI, are associated with severe irAEs. METHODS: Stool samples of cancer patients treated with anti-PD-1 ± anti-CTLA-4 were analyzed using 16S rRNA gene sequencing and metagenomic shotgun sequencing. Differences in alpha and beta diversity between patients with and without severe irAE were assessed, as well as differential relative abundance (RA) of taxa, MetaCyc pathways, and seven prespecified literature-based bacterial groups including pathobionts and Ruminococcaceae. FINDINGS: We analyzed 497 samples of 195 patients before and soon after starting ICI, at severe irAE onset and after starting immunosuppression. Mean RA of the pathobionts group was significantly higher in patients who developed a severe irAE (8.2 %) compared to those who did not (4.8 %; odds ratio 1.40; 95 %CI 1.07-1.87) at baseline, and also early during ICI treatment and at severe irAE onset. A significantly stronger decrease in RA of Ruminococcaceae after starting ICI was observed in patients who developed a severe irAE compared to those who did not. RAs of Ruminococcaceae, the genus Ruminococcus, and the species R. bromii and R. callidus were significantly lower at severe irAE onset compared to other time points. INTERPRETATION: Gut microbiome dysbiosis signaled by higher RA of pathobionts and decrease in RA of Ruminococcaceae may predispose to severe irAEs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Verheijden RJ, van Eijs MJM, Paganelli FL, et al. Gut microbiome and immune checkpoint inhibitor toxicity. Eur J Cancer. 2025. PMID: 39793444. doi:10.1016/j.ejca.2025.115221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。